Impairment of recall improves tolerance of cytotoxic chemotherapy.
D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008140:Lorazepam / Q000494:pharmacology*; D008568:Memory / Q000187:drug effects*; D011939:Mental Recall / Q000187:drug effects*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D014151:Anti-Anxiety Agents; D000970:Antineoplastic Agents; D006220:Haloperidol; D008140:Lorazepam